title: Independent and additive effects of atenolol and methionine restriction on lowering rat heart mitochondria oxidative stress.
abstract: A low rate of mitochondrial ROS production (mitROSp) and a low degree of fatty acid unsaturation are characteristic traits of long-lived animals and can be obtained in a single species by methionine restriction (MetR) or atenolol (AT) treatments. However, simultaneous application of both treatments has never been performed. In the present investigation it is shown that MetR lowers mitROSp and complex I content. Both the MetR and the AT treatments lower protein oxidative modification and oxidative damage to mtDNA and the fatty acid unsaturation degree in rat heart mitochondria. The decrease in fatty acid unsaturation seems to be due, at least in part, to decreases in desaturase and elongase activities or peroxisomal β-oxidation. Furthermore, the phosphorylation of extracellular signal-regulated kinase (ERK) was stimulated by MetR and AT. The decrease in membrane fatty acid unsaturation and protein oxidation, and the changes in fatty acids and p-ERK showed additive effects of both treatments. In addition, the increase in mitROSp induced by AT observed in the present investigation was totally avoided with the combined MetR + AT treatment. It is concluded that the simultaneous treatment with MetR plus atenolol is more beneficial than either single treatment alone to lower oxidative stress in rat heart mitochondria, analogously to what has been reported in long-lived animal species.
authors: Department of Animal Physiology-II, Faculty of Biological Sciences, Complutense University of Madrid (UCM), Madrid, Spain.
authors: Ines
authors: I
authors: Sanchez-Roman
authors: Alexia
authors: A
authors: Gomez
authors: Alba
authors: A
authors: Naudí
authors: Mariona
authors: M
authors: Jove
authors: Jose
authors: J
authors: Gómez
authors: Mónica
authors: M
authors: Lopez-Torres
authors: Reinald
authors: R
authors: Pamplona
authors: Gustavo
authors: G
authors: Barja
mesh_terms: D000284:Administration, Oral; D058671:Adrenergic beta-1 Receptor Antagonists / Q000008:administration & dosage; D000818:Animals; D001262:Atenolol / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004357:Drug Synergism; D005227:Fatty Acids / Q000378:metabolism*; D008297:Male; D008715:Methionine / Q000008:administration & dosage / Q000378:metabolism*; D008929:Mitochondria, Heart / Q000187:drug effects / Q000502:physiology*; D051336:Mitochondrial Membranes / Q000187:drug effects / Q000378:metabolism*; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D005227:Fatty Acids; D017382:Reactive Oxygen Species; D001262:Atenolol; D008715:Methionine